About
Medical-grade Cannabinoids
Enzymogen has developed a technology platform to manufacture medical-grade cannabinoids. The company uses enzymatic processes to convert natural resources into commercially viable products and improve the efficiency of existing products while maximizing the possibility of commercially viable byproducts. Enzymogen's core functions include full-package projects from clone to final enzyme; clone development in mammals, bacteria, yeast, and algae; process development and optimization; fermenter/bioreactor scale-up; establishment of analytical methods for in-process and release testing; and GMP manufacturing. The company's current product offering includes Taq DNA polymerase (nonbacterial source), human gastric lipase, phospholipase C and D, and cholesterol esterase YEH1 and TGL1.
Identity
| Name | Enzymogen |
|---|---|
| Slug | enzymogen |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoNG7vNQKDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Sep 2022 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Yavne |
| HQ address | Hidekel St 19, Yavne, Israel |
Web & social
| Website | https://www.enzymogen-bio.com/ |
|---|---|
| https://www.linkedin.com/company/10494325 | |
| https://www.facebook.com/enzymogen |
Classifications
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}